Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 January 2024 | Story Leonie Bolleurs
UFS scientists contribute to the battle against cancer
From top left, moving clockwise: Dr Nerina van der Merwe, Dr Osayande Evbuomwan, Prof Alicia Sherriff, Profs Andreas Roodt and Alice Brink.

Cancer stands as a prominent contributor to deaths worldwide, with a big impact on families and communities. Prostate cancer is one of the leading causes of mortality in the world. The recent diagnoses of cervical cancer are 10 702 annually, with 5 870 patients passing away. Female breast cancer surpassed lung cancer as the most commonly diagnosed cancer in 2020 (American Cancer Society), representing 11,7% of all cancer cases, making it the fifth leading cause of cancer mortality worldwide. Researchers at the university are doing their part in the fight against cancer.

Treating prostate cancer

In July 2021, Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, along with a team of university doctors, initiated patient treatment using radioligand therapy (RLT). This targeted nuclear medicine therapy delivers high radiation levels precisely to cancer cells, minimising damage to normal organs and tissue, a benefit not typically provided by conventional therapies.

It was the first time that Lutetium 177 PSMA – a type of PRRT – has been used to treat patients with metastatic castrateresistant prostate cancer (MCRPC) in the Free State, providing hope when standard treatments and conventional therapy are not an option. This treatment generally enhances quality of life, slows disease progression, and extends overall survival, with minimal side effects.

All three patients treated with Lu 177 PSMA so far have completed at least four therapy cycles and tolerated it well. The first two patients, while initially responding well, sadly passed away due to unrelated causes. The third case stands out as the most successful, responding excellently to seven treatment cycle and remaining in good health.

Dr Evbuomwan recently also obtained a license for a more effective therapy, AC 225 PSMA, as an alternative to Lu 177 PSMA.

Precise cervical cancer therapy

Medical personnel at the Universitas Academic Hospital also became the first in Southern Africa to use interstitial brachytherapy as a method for treating cervical cancer. Prof Alicia Sherriff, Head of the Department of Oncology, explains that brachytherapy – a form of internal radiation therapy – places the radiation source near or inside the cancer. “Precise delivery of curative doses to the cancer protects surrounding organs such as the bladder, rectum, and small bowel,” she explains.

Three to five weekly brachytherapy sessions under conscious sedation usually begins after two weeks of daily external beam radiation. On brachytherapy days, external beam radiation is not administered. “The intracavitary brachytherapy applicators are placed within the cervix and uterus and deliver high doses locally, but for surrounding tissue infiltration, additional needles are inserted via the Venezia applicator, delivering high-dose radiation while sparing organs,” says Prof Sherriff.

Their work aligns with the broader goals of the university and its commitment to advancing health care in the region by ensuring the continued growth of their skills and technology, while applying these skills to improve the possibility of disease control, cure or palliation with quality of life.

Familial breast and ovarian cancer testing

Dr Nerina van der Merwe, a principal medical scientist in the Division of Human Genetics, and colleagues are engaged in breast cancer research. They are involved in translational research using new technologies that, once validated as a first-tier diagnostic test, could revolutionise genetic testing for familial breast and ovarian cancer in South Africa when used in conjunction with genetic counselling. This parallel application is ideally suited for primary hospitals and rural clinics, as it will dramatically increase accessibility and uptake of genetic testing in rural areas.

By performing first-tier genetic testing at a community clinic, patients no longer have to be transported to tertiary hospitals for testing, and more patients and related family members who are unaware of a familial predisposition will be reached. “By warning unaffected related individuals about their potential increased risk, we can play a part in the earlier detection or diagnosis of patients, improving their cancer survival rate,” states Dr Van der Merwe.

Patenting cancer research

Prof Andreas Roodt, a retired Distinguished Professor in the Department of Chemistry, and colleagues – particularly Prof Alice Brink and co-worker Prof Roger Alberto from the University of Zurich – have published widely on the chemistry of radiopharmaceutical models. Since the 2000s, the world has introduced the concept of ‘theranostics,’ which involves the use of a single compound for both cancer detection and therapy. “These compounds contain a radioisotope that provides internal radiation for cancer detection (diagnostic) and a second part for treatment,” explains Prof Roodt.

Their research enables the high-yield preparation of compounds containing multiple isotopes often present in very low concentrations. “This allows combining diagnostic isotopes such as technetium-99m (used in >80% of diagnostic patient studies worldwide) with therapeutic radioisotopes, such as rhenium-186 (used for bone cancer therapy), with ease. Many therapeutic radioisotopes do not have good diagnostic radiation; thus, by combining the two types of radioisotopes in one medicine, the oncologist can now clearly see where the therapeutic part is going and apply more effective treatment,” he says.

News Archive

UFS shines in MBA survey
2006-10-25

Here are Prof Tienie Crous (Dean: Faculty of Economic and Management Sciences at the UFS) and Prof Helena van Zyl (Director of the UFS School of Management) with a copy of the Financial Mail.
Photo: Leonie Bolleurs

UFS shines in MBA survey
According to a recent survey published in the Financial Mail, the MBA programme presented by the School of Management at the University of the Free State (UFS) was rated jointly second best in the country by its graduates in terms of quality and standard.
The UFS MBA Programme was also rated fourth best by its graduates in terms of relevance to their business.

“I am overwhelmed and very proud that the School of Management, although we are a young school and have only been in existence for 7 (seven) years, has been rated so high by our graduandi. The School contributes in a very special way to much-needed business training in central South Africa,” said Prof Helena van Zyl, Director of the UFS School of Management.

“According to the survey, we have the lowest acceptance rate of applicants for the MBA programme, with only 33 students being accepted out of every 100 who apply.  In general, we do not compromise on quality – as stated by our slogan: Be worth more.  Given the quality of the programme, our MBA is very affordable – it offers real value for money,” said Prof van Zyl.

According to Prof van Zyl, the School of Management has had an increase the past 6 (six) months in enquiries from prospective students from Gauteng who are interested in studying the MBA programme.  “They are even prepared to travel to Bloemfontein to attend classes,” she said. 

This year Financial Mail moved away from an overall MBA ranking to a detailed consideration of subject area strengths for each business school in South Africa.  The subject Strategy offered at the UFS School of Management was rated second in the country while the subject Economics also received the same rating.

“The School of Management is the flagship of the Faculty of Economic and Management Sciences.  It gives the UFS and this faculty a standing in corporate South Africa.  This is largely due to Prof Helena van Zyl’s strategy to position the school and making it visible on a national level,” said Prof Tienie Crous, Dean: Faculty of Economic and Management Sciences at the UFS.

According to Prof Crous, the UFS School of Management provides students with opportunities to obtain first-hand experience of how big and successful companies are managed.  “For instance, our MBA students undertake an overseas study tour every year.  This year they visited amongst others the headquarters of Airbus in Toulouse, France and next year they will be visiting the headquarters of Toyota and Yamaha in Japan,” said Prof Crous.

Media release
Issued by: Lacea Loader
Media Representative
Tel:   (051) 401-2584
Cell:  083 645 2454
E-mail:  loaderl.stg@mail.uovs.ac.za
24 October 2006

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept